# Rigel Pharmaceuticals (RIGL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RIGL
## Company Profile
- Ticker: RIGL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Hematology
## Stock Data
- Close: 48.67 USD
- Market cap: 555432441.6 USD
- Last updated: 2026-09-04
## Business Overview
### Hematology and Oncology
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer. It combines a growing portfolio of marketed medicines with internally developed and licensed clinical programs.
### TAVALISSE
TAVALISSE, or fostamatinib, is Rigel's therapy for chronic immune thrombocytopenia. It anchors the company's commercial hematology franchise and is sold directly in the United States and through international partners.
### GAVRETO and REZLIDHIA
GAVRETO, or pralsetinib, targets RET-altered cancers, while REZLIDHIA, or olutasidenib, treats relapsed or refractory IDH1-mutated acute myeloid leukemia. Together they extend Rigel's commercial presence into precision oncology.
### VEPPANU
VEPPANU, or vepdegestrant, is an FDA-approved PROTAC for ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. Rigel licensed global development, manufacturing and commercialization rights from Arvinas and Pfizer.
### R289
R289 is an oral prodrug of a dual IRAK1/4 inhibitor in Phase 1b development for relapsed or refractory lower-risk myelodysplastic syndrome. The program is evaluating dose expansion and selection of a recommended Phase 2 dose.
## Why The Stock Is Moving

As of Sep 4, 2026, RIGL closed up 0.35% at $48.67. No new same-company headline was identified in the current news window.

## Future Catalysts

- U.S. commercial availability of VEPPANU in mid-August 2026.
- Completion of R289 Phase 1b dose-expansion enrollment and selection of a recommended Phase 2 dose in the second half of 2026.
- Preliminary R289 dose-expansion data by year-end 2026.

## Recent News
- 2026-09-02 12:05 EST — [Rigel to Participate in Upcoming September Investor Conferences](https://biopharmsignal.com/news/RIGL/rigel-to-participate-in-upcoming-september-investor-conferences-ea3b8424) — Source: Rigel Pharmaceuticals
- 2026-08-13 12:05 EST — [Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer](https://biopharmsignal.com/news/RIGL/rigel-announces-availability-of-veppanu-vepdegestrant-for-patients-with-er-her2--ca880f7c) — Source: Rigel Pharmaceuticals
- 2026-08-04 20:01 EST — [Rigel Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-reports-second-quarter-2026-financial-results-abcb40e5) — Source: Rigel Pharmaceuticals
- 2026-07-28 12:05 EST — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a) — Source: Rigel Pharmaceuticals
- 2026-07-01 12:05 EST — [Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/RIGL/rigel-appoints-board-member-alison-l-hannah-m-d-as-chief-medical-officer-c2f47409) — Source: Rigel Pharmaceuticals